Mark Rubinstein to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Mark Rubinstein has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
0.519
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.486
-
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Ra Complexes Enhances Tumor Control. Cancer Immunol Res. 2019 08; 7(8):1371-1380.
Score: 0.033